Liquid Biopsy Market

Industry Overview

The global liquid biopsy market is expected to grow from USD 5.39 billion in 2023 to USD 20.41 billion by 2030 at a compound annual growth rate (CAGR) of 14.23% during the forecast period ranging from 2025 to 2030.

Liquid biopsy is a medical process of transforming diagnostics by analyzing biomolecules such as DNA, RNA, and proteins in bodily fluids such as blood. Unlike invasive traditional biopsies, it is non-invasive, offering vital diagnostic insights into conditions such as cancer without surgery. Liquid biopsies show immense promise in enhancing cancer detection and management, resulting in a giant leap in medical innovation. A liquid biopsy is a blood test that detects cancer cells or DNA circulating in the blood, called “circulating tumor DNA” or “ctDNA.” A liquid biopsy detects the small pieces of DNA in the bloodstream from these cancer cells. A liquid biopsy, however, is performed using a simple blood draw, which is sent to a laboratory for analysis.

The global liquid biopsy market is growing at a fast rate due to the rising occurrence of cancer and higher emphasis on personalized medicine. Different product and services contribute to the market of which the assay kits have high demand due to higher need for biopsy tests, the requirement for reliable and accurate assays, and higher applications. The rising number of mergers and acquisition, better product offerings, and growing emphasis on geographic expansion are the major factors for the growth of the liquid biopsy market.

The lower scalability of liquid biopsy techniques due to the shortage of skilled professionals to conduct these intricate tests limits the widespread adoption and market expansion. The growth prospects are however brightened due to the changing perspective in emerging economies such as India and China regarding the usage of the technology and its growing adoption for the treatment of rare cancer.

Market Segmentation

Insight by Product and Services

The global liquid biopsy market is divided on the basis of product and services into assay kits, services, and instruments. Out of these, the assay kits segment will account for the largest share during the forecast period due to the growing need for dependable and precise assays and higher applications of liquid biopsies.

Insight by Circulating Biomarker

The global liquid biopsy market is divided on the basis of circulating biomarker into circulating tumor cells, circulating nucleic acids, extracellular vesicles (Evs), circulating tumor DNA (CtDNA), cell-free DNA, and other circulating biomarkers. Out of these segments, the circulating nucleic acids biomarker segment will hold the largest market share during the forecast period due to widespread applications related with ctDNA in liquid biopsy.

Insight by Clinical Application

The global liquid biopsy market is divided on the basis of clinical application into early cancer screening, treatment monitoring, recurrence monitoring, and therapy selection. Among these segments, the therapy selection segment will account for the largest share during the forecast period due to its immense effectiveness and assistance in therapy assortment and the ability to improve patient outcomes. The early screening segment is also expected to show at a high CAGR due to growing prevalence of multiple cancers and higher need to provide efficient methods to detect them. The treatment monitoring segment is also quite dominating due to increased awareness and adoption.

Insight by Application

The global liquid biopsy market is divided on the basis of application into cancer applications and non-cancer applications, where the latter is expected to account for the largest share in the market during the forecast period due to the rising occurrence of cancer and rising adoption of liquid biopsy technology in early detection for cancer. 

Insight by End User

The global liquid biopsy market is divided on the basis of end users into reference laboratories, academic and research centers, hospitals and physician laboratories, and other segments. Among all these segments, the reference laboratories will account for the largest share due to the increasing volume of test samples subcontracted to them.

The hospitals and laboratories end-use segment will also dominate the market being a preferred source of care and availability of different services under one roof, and ability to offer quick results for tests in emergencies.

Indisght by Technology

The global liquid biopsy market is divided on the basis of technology into NGS, PCR, FISH, and other segments. Out of all these the NGS or next generation sequencing segment will account for the highest revenue share due to the higher efficiency to detect cancer variants even the lower frequency, tech developments, and increased adoption.

Global Liquid Biopsy Market Report Coverage

Report Metric	Details
Historical Period	2018 - 2023
Base Year Considered	2024
Forecast Period	2025 - 2030
Market Size in 2023	U.S.D.  5.39 Billion
Revenue Forecast in 2030	U.S.D.  20.41 Billion
Growth Rate	14.23%
Segments Covered in the Report	By Product and Services, By Circulating Biomarker, By Clinical Application, By Application, By Technology and By End User
Report Scope	Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report	North America, Europe, Asia-Pacific, Middle East, South America and Rest of the World

Industry Dynamics

Industry Trends

The key trends noticed in the liquid biopsy market include a number of mergers and acquisition among the major players to expand their product line and efficiency of the same. In addition, there is also a growing need for liquid biopsy noticed based on specific and improving geographic presence which is promoting the market and is strengthening the position of the labs to perform next-generation sequencing application.

Growth Drivers

The major growth factors of the global liquid biopsy market are the higher preference for noninvasive procedures and the growing investment in research and development. In addition, supportive government initiatives and by other organizations to promote innovative technologies to use in diagnosis, technological advancements, rising awareness regarding the availability of different non-invasive treatments, the rising prevalence of breast cancer among the female population, the benefits associated with the new liquid biopsy techniques, higher adoption of the liquid biopsy among the patients across the globe are all fueling the market growth.

Challenges

The major setbacks to the growth of the global liquid biopsy market include low sensitivity and specificity, uncertain regulatory, unsupportive reimbursement scenario and the high cost involved in such tests due to the use of advanced technologies and specialized equipment.

Opportunities

The growth opportunities to the market are however offered by growing awareness of innovative technology and personalized medicine for cancer patients, the rise in demand for non-invasive liquid biopsy techniques due to its impact on cancer diagnosis, and growing advancements in precision medicine due to liquid biopsy.

Geographic Overview

North America is the largest contributor to the liquid biopsy market because the region witnesses a high occurrence of cancer cases. In addition, easy availability of the test and growing adoption of innovative diagnostic technologies in healthcare are also fueling the market growth in this region.

On the other hand, Asia Pacific is expected to grow during the forecast period due to increasing disposable income, rising healthcare expenditure, growing awareness regarding the liquid biopsy techniques, and higher adoption of the advanced techniques in the hospitals, clinics, and diagnostic laboratories for the diagnosis. In addition, the increasing penetration of hospitals and diagnostic centers in the region is also expected to fuel the growth of the liquid biopsy market.

Competitive Insight

Key players in the liquid biopsy industry are catering to the demand of these devices by investing in technologically advanced products in their product portfolio across the globe. Biocept, Inc., Roche Diagnostics, Trovagene, Inc., Illumina, Inc., QIAGEN N.V., Menarini-Silicon Biosystems, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Genomic Health, Inc., Guardant Health, Inc., and MdxHealth SA are the key players offering liquid biopsy products.

Biocept, Inc. develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS).

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function.

Recent Developments by Key Players

Manipal Academy of Higher Education (MAHE) and Roche Diagnostics India Pvt Ltd. collaborated to create a Centre of Excellence (CoE). This partnership aims to enhance skill development and innovation in the field of diagnostics. This collaboration represents a significant step forward in combining the strengths of both academia and industry to improve healthcare diagnostics.

Illumina Inc. (a global leader in DNA sequencing and array-based technologies) has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence of disease following clinical intervention.

The Liquid Biopsy Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

• By Product and Services
  • Assay Kits
  • Services
  • Instruments
• By Circulating Biomarker
  • Circulating Tumor Cells
  • Extracellular Vesicles (Evs)
  • Circulating Tumor DNA (CTDNA)
  • Cell-Free DNA
  • Other Circulating Biomarkers
• By Clinical Application
  • Early Cancer Screening
  • Treatment Monitoring
  • Recurrence Monitoring
  • Therapy Selection
• By Application
  • Cancer Applications
    • Liver Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Breast Cancer
    • Other Cancers
  • Non-Cancer Applications
• By End User
  • Reference Laboratories
  • Academic and Research Centers
  • Hospitals and Physician Laboratories
  • Other End Users

Region Covered in the Report

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World (RoW)
  • Brazil
  • Saudi Arabia
  • South Africa
  • U.A.E.
  • Other Countries

Source: VynZ Research

Source: VynZ Research